Skip to main content
. 2020 Sep 25;10(10):219. doi: 10.3390/life10100219

Figure 1.

Figure 1

Summary of reviewed biomarkers of response to immune checkpoint inhibitor (ICI) therapies for melanoma patients. PD-L1: programmed death ligand 1, MHC I: major histocompatibility complex class I, MHC II: major histocompatibility complex class II, ctDNA: circulating tumor DNA, MDSC: myeloid-derived suppressor cells, Tregs: regulatory T-cells, TIL: tumor infiltrating lymphocytes.